Ahmed Mohamed Ali Aref

Ahmed Mohamed Ali Aref

Auto-generated profile, based on publicly available information

Ahmed Mohamed Ali Aref


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2025 in ASIDE Internal Medicine
Verified
Journal Article
Open access
AAAhmed Mohamed Ali Aref
Ahmed Mohamed Ali Aref
AAAhmed H. Abdelwahed
Ahmed H. Abdelwahed
ANAbdelrahman Nassar
Abdelrahman Nassar
MEMohamed Elshennawy
Mohamed Elshennawy
MMMaryam Massoud
Maryam Massoud
MAMostafa Alfishawy
Mostafa Alfishawy
Background: Living donor liver transplantation (LDLT) is a crucial therapeutic option for patients with end-stage liver disease in Egypt, where deceased donor grafts are scarce. This study aims to investigate the challenges and infectious complications associated with LDLT in Egypt. Methods: A comprehensive review of relevant literature was conducted, focusing on factors affecting donor selection, the prevalence of infections in recipients, and the impact of healthcare providers' knowledge on organ donation. The study included data on complications affecting donors and recipients in the context of LDLT. Results: The high prevalence of the hepatitis C virus and poverty in Egypt negatively impact the live donor pool. Lack of knowledge about liver donation, inadequate media coverage, and family pressure contribute to the low number of liver donors. Infectious complications play a significant role in the outcomes of LDLT, with bacterial infections being the most common. Donors also experience complications, with intraabdominal collections and pneumonia being the most frequent. Healthcare providers' knowledge and attitudes toward organ donation need improvement, and educational efforts should be tailored to the cultural and religious context. Conclusion: Addressing the challenges in donor selection, raising public awareness about organ donation, and improving healthcare providers' knowledge are essential steps toward optimizing LDLT outcomes in Egypt. Moreover, it is crucial to monitor and manage infectious complications in both donors and recipients to ensure the success of the transplantation process.

1 June 2026 in Annals of Translational Medicine
Verified
Journal Article
Open access
OAOmar Abdelhalim
Omar Abdelhalim
MYMohammed Youssef
Mohammed Youssef
SASawsan Al-Lababidi
Sawsan Al-Lababidi
MEMohamed Eldesouki
Mohamed Eldesouki
AMAhmed Mohamed
Ahmed Mohamed
HAHazem Abosheaishaa
Hazem Abosheaishaa
Patients with coexisting type 2 diabetes mellitus (T2DM) and inflammatory bowel disease (IBD) represent a high-risk population with competing comorbidities, complex medication regimens, and overlapping inflammatory pathways. Although the role of sodium-glucose co-transporter-2 (SGLT2) inhibitors in managing type 2 diabetes is well-established, their impact on outcomes in diabetic patients with coexisting IBD remains unclear. This study aimed to investigate the association between SGLT2i use and hospitalization, intensive care unit (ICU) admission, mortality, IBD-related complications, and surgical procedures in diabetic patients with IBD. We conducted a retrospective cohort study using the TriNetX Global Collaborative Network. Cohort 1 comprised diabetic patients with IBD who received SGLT2 inhibitors with at least three dispensations within one year of IBD diagnosis, and Cohort 2 comprised diabetic patients with IBD never prescribed SGLT2i, matched on baseline characteristics, comorbidities, IBD-specific medications, and laboratory values, yielding 3,950 patients per cohort. Clinical outcomes were evaluated at 1 and 5 years following the index event. At 1 year, hospitalization, ICU admission, and mortality were significantly lower in Cohort 1 [risk ratio (RR): 0.886, P<0.001; RR: 0.851, P=0.03; and RR: 0.525, P<0.001, respectively]. Kaplan-Meier analysis demonstrated improved survival in Cohort 1 [94.27% vs. 88.76%, P<0.001; hazard ratio (HR): 0.490]. IBD-related complications and surgical procedures were also significantly reduced (RR: 0.879, P=0.004 and RR: 0.548, P=0.02, respectively). At 5 years, hospitalization, ICU admission, and mortality remained significantly lower in Cohort 1 (RR: 0.932, P=0.002; RR: 0.848, P=0.003; and RR: 0.545, P<0.001, respectively). Kaplan-Meier analysis continued to demonstrate improved survival in Cohort 1 (85.01% vs. 74.95%, P<0.001; HR: 0.532), whereas IBD-related complications and surgical procedures were numerically lower but no longer statistically significant (RR: 0.954, P=0.18 and RR: 0.741, P=0.15, respectively). SGLT2i therapy in diabetic patients with IBD was associated with reduced hospitalization, ICU admission, and mortality, with persistent benefits observed at both 1 and 5 years of follow-up. Reductions in IBD-related complications and surgical procedures were observed, particularly at 1 year. These findings suggest a potential disease-modifying role warranting further prospective investigation.